The hypolipidemic activity of CA in a zebrafish model. (A) Vena caudalis (green dashed line) stained with ORO in the zebrafish; (B) effect on lipid lowering of CA in the zebrafish.

The antithrombotic activity of CA in a zebrafish model. (A) Cardiac red blood cells (green dashed line) stained with dianisidine in the zebrafish. (B) Thrombosis inhibition rate of CA in the zebrafish. All data are represented by their mean ± SE.

Interaction target analysis. (A) “CA-Target” network; (B) Venn diagram and intersection targets of CA, hyperlipidemia, and thrombosis.

The PPI network of the 35 CA, hyperlipidemia, and thrombosis intersection targets.

GO functional and KEGG pathway enrichment analysis. (A) BP, MF, and CC in the GO analysis (p < 0.01); (B) the signaling pathways identified in the KEGG pathway enrichment analysis (p < 0.01).

The molecular docking results of CA with core hyperlipidemia and thrombosis targets. (A) CA with PRKACA (PDB ID: 5M6Y); (B) CA with ESR1 (PDB ID: 7NFB); (C) CA with HNF4A (PDB ID: 8C1L); (D) CA with HSP90AA1 (PDB ID: 6TN5); (E) CA with IL2 (PDB ID: 7M2G); (F) CA with MMP9 (PDB ID: 6ESM); (G) CA with MMP2 (PDB ID: 7XJO); (H) CA with APP (PDB ID: 2FMA); (I) CA with PRKCA (PDB ID: 2GZV); (J) CA with RELA (PDB ID: 8ONV).

The structure formulas of main compounds in V. dunalianum.

Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Molecules